The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32––35 weeks: a Canadian-based analysis**

By Lanctôôt Krista L.   Masoud Shababa T.   Paes Bosco A.   Tarride Jean-Eric   Chiu Aaron   Hui Charles   Francis Philip L.   Oh Paul I.  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3223-3237

Informa Healthcare

Access to resources Recommend Favorite

Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada

By Paes Bosco   Cole Mara   Latchman Andrew   Pinelli Janet  

Current Medical Research and Opinion, Vol. 25, Iss. 9, 2009-09 ,pp. : 2191-2196

Informa Healthcare

Access to resources Recommend Favorite

Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis

By Joan L. Robinson   Krista L. Lanctôt  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1631-1633

Informa Healthcare

Access to resources Recommend Favorite

Risk of respiratory syncytial virus infection in infants with congenital cystic lung disease

By  

PEDIATRICS INTERNATIONAL, Vol. 57, Iss. 2, 2015-04 ,pp. : 253-257

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antenatal corticosteroid treatment in singleton, small‐for‐gestational‐age infants born at 24–31 weeks’ gestation: a population‐based study

By  

BJOG : AN INTERNATIONAL JOURNAL OF OBSTETRICS & GYNAECOLOGY, Vol. 123, Iss. 11, 2016-10 ,pp. : 1779-1786

John Wiley & Sons Inc

Access to resources Recommend Favorite